IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer

NCT03655002 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Hepatocellular Carcinoma
Refractory Liver Carcinoma
Stage IV Hepatocellular Carcinoma AJCC v8
Stage IVA Hepatocellular Carcinoma AJCC v8
Stage IVB Hepatocellular Carcinoma AJCC v8

Interventions

DRUG: Cyclophosphamide
BIOLOGICAL: Cytokine-based Biologic Agent IRX-2
BIOLOGICAL: Nivolumab

Sponsor

City of Hope Medical Center

Collaborators

[object Object]